KRAS mutations are known to confer resistance to cetuximab in colorectal cancer [81,82], and while this is unclear in EAC due to the rarity of KRAS mutations and unselected patient populations [78,83], KRAS-mutant tumors in our dataset bore the same mutations in codons 12 and 13 as the resistant colorectal tumors and were non-responders. The gene discussed is KRAS; the disease is colorectal neoplasm.